Kaival Brands Innovations Group Inc. (KAVL)

The QualityStocks Daily Newsletter would like to spotlight Kaival Brands Innovations Group Inc. (KAVL).

Kaival Brands (NASDAQ: KAVL), a company focused on developing products into mature, dominant brands, is looking to launch a new line of proprietary cannabidiol (“CBD”) products. The company intends to follow a similar design path set by its highly successful Bidi(R) Stick product, the number one electronic nicotine delivery systems (“ENDS”) offering in the U.S. market, while using the same first-in-class, patented delivery mechanism that gives its consumer base a unique and premium vaping experience. “Along with providing users with a convenient, smoke-free delivery method for CBD, KAVL’s industrial-grade hemp formula promises greater bio-availability than many market competitors, resulting in less product used and overall superior consumer experience,” reads a recent article. According to Niraj “Raj” Patel, Kaival Brands founder and CEO, the company’s mission “is to set new industry standards by providing the highest quality and most effective products in the hemp CBD marketplace.” To view the full article, visit https://ibn.fm/Z7Q7k

Kaival Brands Innovations Group Inc. (KAVL) is focused on growing and incubating innovative and profitable products into mature, dominant brands. It aims to develop internally, acquire or exclusively distribute these products, helping them grow into market-share leaders by providing superior quality that is recognizable in their individual industries.

Formerly known as Quick Start Holdings Inc., the company changed its name to Kaival Brands Innovations Group Inc. (also known as Kaival Brands) in July 2019. Headquartered in Grant, Florida, the company commenced business operations on March 9, 2020.

Bidi™ Stick – Revolutionizing the Vaping Experience

On March 9, 2020, Kaival Brands entered into a partnership with Bidi Vapor LLC. The latter granted Kaival Brands exclusive global distribution rights for the innovative Bidi™ Stick.

Bidi™ Stick is a completely self-contained disposable product that is tamper-proof and recyclable. The innovative product is made from high-quality components and equipped with a long-lasting battery and class A nicotine. Its product engineering also includes a sensitivity control system, along with a proven mechanism designed to help identify and eliminate counterfeit products.

Available in 11 flavors, the Bidi™ Stick offers a premium vaping experience for adult consumers only. From its packaging design to its marketing strategies, Bidi Vapor makes sure that everything is compliant with government regulations.

On March 31, 2020, Kaival Brands partnered with QuikfillRx Digital as a digital service provider to help promote and commercialize the Bidi™ Stick. As a direct result of the partnership, Kaival Brands received back-to-back orders for the vaping device, totaling approximately $135,000, from sizable national convenience chains.

On September 8, 2020, the company announced that Bidi Vapor had submitted its Premarket Tobacco Product application (PMTA) to the U.S. Food and Drug Administration (FDA) for review. In total, over 285,000 pages of research, studies and surveys were submitted to support the application of Bidi™ Stick’s 11 variants.

“We are confident that, upon review, the FDA will authorize Bidi Vapor’s Bidi™ Stick for continued marketing in the United States,” Niraj Patel, President and CEO of Kaival Brands, stated in a news release (http://nnw.fm/unAyG).

Bidi Vapor is an industry leader in recycling – a position that was furthered through the creation of the Bidi Cares Initiative. The program encourages users to recycle their used Bidi™ Sticks instead of trashing them. As motivation, Bidi Vapor offers a free Bidi™ Stick for every 10 used devices recycled by a consumer. Kaival Brands is the exclusive recycling provider for the initiative.

Partnership Impact and Market Outlook

Bidi Vapor is a related party to Kaival Brands, as it is owned by Kaival Brands CEO Nirajkumar Patel. Patel is also the majority stockholder of Kaival Brands, placing both entities under common control.

The partnership has already had a positive impact on Kaival Brands, helping the company expedite growth, as evidenced by its Q2 financial results. According to Kaival Brands’ consolidated fiscal results for the quarter that ended on April 30, 2020, its revenues grew to approximately $22.5 million from no revenue in the same quarter of 2019. The company also scored a gross profit of $4.2 million for the three-month period. Net income was reported at $2.8 million for the quarter, compared to a net loss of about $4,000 in the second quarter of 2019. The company ended the second quarter of 2020 with a cash balance of $2 million (http://nnw.fm/44sq4).

The positive results are primarily an effect of Bidi™ Stick distribution amid the growing worldwide demand for high-quality vape products, as Patel explained in a news release. “Our focus now is to continue to increase revenues by increasing Bidi Vapor’s market share in the vaping industry,” he added.

Internationally, Kaival Brands has already taken steps to expand distribution of the Bidi™ Stick into Guam, Canada, the European Union, the United Kingdom, Australia and New Zealand.

To this end, the company has set up a market engagement and sales force to reach a higher volume of retail and wholesale customers. It also created a dedicated customer support team to provide high-quality service and an enhanced customer experience.

Kaival Brands is dedicated to developing innovative and viable options for adults who use tobacco and vape products and want a premium experience. The company wants to set higher standards to transform perceptions and elevate consumer experience in the vape and CBD industries, with a goal of increasing market share in the ever-growing vaping industry. In 2019, the reported global market for the vaping industry alone was $12.4 billion. These forecasts indicate a potential CAGR of 23.8% through 2027.

Cancellation of 300 Million Shares of Common Stock

In August 2020, the company canceled 300 million shares of common stock, marking a 52.1 percent reduction in its issued and outstanding shares of common stock (http://nnw.fm/W7s9T). Currently, the company’s outstanding common shares total 277,282,630. The cancelation was done in exchange for three million shares of Series A Preferred Stock. The Series A Preferred Stock cannot be converted before November 2023, barring any event that may trigger early conversion.

According to Patel, this move will benefit all shareholders and help maintain stability of the market pricing of remaining common stock. The overall goal is to increase value for long-term investors.

Management Team

Nirajkumar Patel is the CEO, CFO, President, Treasurer and Director of Kaival Brands and owner of Bidi Vapor LLC. In 2004, Patel received a Bachelor of Science in pharmaceutical sciences from AISSMS College of Pharmacy in Prune, India. He moved to the United States in 2005, and he continued his education at the Florida Institute of Technology, where he graduated in 2009 with a master’s degree in medicinal and pharmaceutical chemistry. He currently holds a Six Sigma Black Belt Certification.

Eric Mosser is the COO, Secretary and Director of Kaival Brands. Mosser attended Arizona State University, where he studied business management. In 2004, he graduated from Rio Salado College with an associate degree in applied science in computer technology.

Kaival Brands Innovations Group Inc. (KAVL), closed Wednesday's trading session at $5.68, up 0.530973%, on 9,898 volume with 41 trades. The average volume for the last 3 months is 9,898 and the stock's 52-week low/high is $2.73959994/$43.7999992.

Recent News

• Kaival Brands Innovations Group Inc. (KAVL) - InvestorNewsBreaks - Kaival Brands Innovations Group Inc. (NASDAQ: KAVL) Eyes Launch of New Proprietary CBD Products
• InvestorNewsBreaks - Kaival Brands Innovations Group Inc. (NASDAQ: KAVL) 'More Enthusiastic than Ever' to Harness Exciting Potential
• Kaival Brands Innovations Group Inc. (NASDAQ: KAVL) Welcomes Tougher Vape Regulations as FDA Nears Major PMTA Announcement

Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF)

The QualityStocks Daily Newsletter would like to spotlight Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF).

Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, has revealed the keynote speaker for its upcoming Meet Delic event. Renowned shaman and best-selling author Alyson Charles will speak at the two-day immersive edutainment experience that is designed as an elite gathering for the world's leading psychedelic and wellness thought and business leaders. The event is scheduled for Nov. 6–7, 2021, and will be an in-person gathering at AREA15 in Las Vegas, Nevada. In her keynote address, titled “Surrender & Integration: Creating Soul and Plant Spirit Alignment to Master the Journey,” Charles will share how to connect to one's full divine power and spiritual gifts, including working with psychedelics as a potential process to open oneself up to sacredness. To register for the event, visit https://ibn.fm/7i10Z. To view the full press release, visit https://ibn.fm/qAuvc

Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country.

Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. Its founders helped build the multi-billion-dollar cannabis industry and aim to do the same in psychedelics as it follows a similar path toward legalization. In its quest to advance the new psychedelic renaissance upon us, Delic has become the pioneer in its field, creating an ecosystem of opportunities by investing in cutting-edge ideas.

The Vancouver-based company was formed in 2019 to address the growing interest in psychedelic wellness backed by science. Delic was the ‎first psychedelic umbrella platform. It is currently a trusted source for those interested in ‎psychedelic culture, education, treatments, and more.

While other emerging companies focus on patent medicine and big pharma for substances limited by government regulation, Delic is blazing a unique trail. It identifies ancillary and fully legal opportunities like IP, new media, live events, ketamine clinics (with the ability to offer additional psychedelic treatments once legalized, and large-scale production and brings them under its big tent of resources and reach.

The Big Problems Delic Is Addressing

• Fifty percent of Americans will meet the criteria for a mental health condition sometime in their lifetime. The FDA has approved psilocybin therapy as a breakthrough therapy for depression.
• Every 40 seconds, someone in the world commits suicide. Ketamine has been shown to decrease thoughts of suicide significantly. In 2019, the FDA approved esketamine as a fast-acting antidepressant.
• Traditional palliative care methods do not eradicate end-of-life (EOL) anxiety. LSD and psilocybin have been shown to reduce EOL anxiety for terminally ill patients. Eighty percent of terminally ill patients with psilocybin sessions experienced significant reductions in depression and anxiety.
• Approximately 50 million people in the U.S. are addicted to some tobacco product. Research shows that psilocybin is helping people quit smoking.

The Delic Ecosystem

The Delic Ecosystem covers three main areas: media, health, and science. The media focus is educating and motivating the masses through a variety of digital platforms, like Delic’s Reality Sandwich digital magazine, a free public education platform providing psychedelic guides, news and ‎culture (1.4+ million page views in 2020 and 54k social media followers across all platforms); Meet Delic, the first-ever psychedelic wellness summit and the premier psychedelic wellness event based in Las Vegas (over 2,000 live attendees and 5,000+ email subscribers); and Delic Radio (over 43 episodes and 100k total streams). Delic has also been featured in numerous media outlets like Forbes, NBC News, The Joe Rogan Experience, Daily Beast, High Times, and The Dr. Drew Podcast.

The focus of Delic’s health operations is the most accessible psychedelic treatments that can help billions of people live happier lives. Delic does this through one of the largest ketamine clinic chains in the country, Ketamine Infusion Centers (KICs), a limited liability corporation formed under the laws of Arizona that runs three ketamine clinics located in Bakersfield, California, and Phoenix, Arizona. Its management team has over 15 years of experience in the clinic and medical space, scaling and operating over 20 clinics, with a plan to open 10 more clinics in the next 18 months. Together, these clinics have overseen 4,000+ treatments delivered to date.

The focus of Delic’s science operations is developing IP and advanced extraction and testing facilities that are the backbone of the legal market. Delic carries this out through Delic Labs, a licensed cannabis and psilocybin research laboratory based in Vancouver. It’s the only entity licensed by Health Canada to exclusively focus on research and development of psilocybin vaporization technology.

Founded by award-winning chemists, Delic Labs focuses on extraction optimization, analytical testing, and chemical process development to advance the cannabis and psilocybin industries. Health Canada gave it a Section 56 Exemption to work with psilocybin compounds, allowing the company to possess and research these products for development and quality control before they hit the market.

Latest Acquisition – Homestead Book Company

On March 4, 2021, Delic announced its acquisition of Seattle-based Homestead Book Company. Homestead is a legacy counterculture distributor of psychedelic media. It’s also the creator of one of the first self-contained psilocybin mushroom grow kits.

The acquisition of Homestead is an exciting one, as it shows how Delic is increasing accessibility to this nascent industry within regulated jurisdictions. Homestead has sold tens of thousands of mushroom kits globally and was one of the earliest distributors for High Times and many other counterculture publications.

The Homestead acquisition allows Delic to increase its product offerings on its website, Reality Sandwich, which recently hit a record for average monthly traffic of over 200,000 unique visitors and over 2.6 million active readers in 2020.

Market Outlook

The psychedelic renaissance is here. Just in time to help address the global mental health crises, plant medicines have the potential to help billions of people live happier lives. Thanks to university-led and FDA-approved studies, North America is leading the way in advancing an industry as psychedelics are becoming accepted globally for therapeutic, medical, and recreational use. Here are some statistics:

• 32 million people in the U.S. have used psychedelics at least once
• 17% of all American adults between 21 and 64 have used psychedelics at least once
• $500 billion is spent in the U.S. every year on prescription drugs
• $238 billion is spent in the U.S. every year on mental health treatments and ancillary services
• The anxiety disorder and depression treatment market is estimated at $16 billion
• $187.8 billion was spent in 2013 on mental health and substance abuse disorders

Management Team

Delic Co-Founder and CCO Jackee Stang was an executive at High Times, a leading counterculture publication that became the voice for the cannabis industry. The monthly magazine had a circulation of over 500,000 copies per issue. Its website attracted 500,000 to five million users each month by 2014.

Likewise, company Co-Founder and CEO Matt Stang was a previous owner and operator of High Times, a position from which he played an instrumental in legalizing cannabis in multiple states and launched the Cannabis Cup in America. After interacting with the cannabis community for two decades, he helped found Delic in 2019 as one of the first psychedelic corporations. He shapes the company’s vision and path using his expertise in branding, marketing, business development, and product viability.

Delic’s VP of Business Development, John Coleman, Ph.D., is a former president of Anandia Labs, a biotech company focused on genetics and analytics. Having experience in both science and business, Dr. Coleman is well-equipped to lead Delic’s business development efforts as it strives to enter new vertical markets.

Zak Garcia is the company’s Chief Marketing Officer. He was the former CMO of Bulletproof Inc., maker of the well-known Bulletproof Coffee brand. Mr. Garcia is a marketing and leadership strategist who helped grow Bulletproof Coffee to over $250 million in revenue.

Delic Holdings Inc. (DELCF), closed Wednesday's trading session at $0.2202, up 0.090909%, on 28,552 volume with 25 trades. The average volume for the last 3 months is 28,552 and the stock's 52-week low/high is $0.170000001/$1.03799998.

Recent News

• Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) - InvestorNewsBreaks - Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Announces Meet Delic Keynote Speaker
• InvestorNewsBreaks - Delic Corp Inc. (CSE: DELC) (OTCQB: DELCF) Appoints Members to Newly Formed Medical Advisory Board
• Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Is 'One to Watch'

Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF)

The QualityStocks Daily Newsletter would like to spotlight Avricore Health Inc. (OTCQB: AVCRF).

Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) earlier this year signed a master agreement with Canada’s largest pharmacy network, Shoppers Drug Mart, that would enable patients to access its HealthTab(TM) platform. HealthTab is an innovative point-of-care blood screening and health-data management platform – integrated with Abbott’s Afinion 2 analyzers. Notably, the small, fast and multi-assay analyzers provide valuable point-of-care testing to patients. Avricore then undertook a test rollout of its platform in which over 600 results were reported in the week-and-a-half trial period. A recent article reads, “Following the test rollout, a pharmacist and associate owner of a Shoppers Drug Mart located in Mississauga, Ontario, expressed his excitement at having HealthTab in his store because the platform would demonstrate a new, better way of doing pharmacy practice. ‘This is really profound because having access to lab-accurate results at our fingertips means we can better help family physicians by conducting regular follow up using advanced diagnostics with our diabetic and cardiovascular patients more effectively,’ Mohamed Adel Elsabakhawi had said.” To view the full article, visit https://ibn.fm/tOZvS

Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering, HealthTab™ (a wholly owned subsidiary), the company aims to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacies.

HealthTab

HealthTab is a turnkey point-of-care testing solution that effectively turns pharmacies into diagnostic hubs (sometimes known as ‘Community Diagnostic Centers’, or CDCs) and connects them on a single, cloud-based platform.

The HealthTab network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery and empowers patients to take more control of their health. It also reduces costs and waiting times while providing many potential revenue streams, including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets and third-party app integration through API.

Agreement with Shoppers Drug Mart

In June 2021, Avricore signed a Master Agreement with select Shoppers Drug Mart pharmacies to pilot the HealthTab platform. This agreement gives patients access to point-of-care blood screening and health-data management for potential risks relating to diabetes and cardiovascular conditions using HealthTab-integrated Afinion 2™ analyzers provided by Abbott Rapid Diagnostics.

Avricore is the first pharmacy solutions provider to partner with Abbott (NYSE: ABT), the global health care company and diagnostics leader in Canada. In May 2021, the company signed a supplier distribution agreement to expand the distribution of Abbott’s Afinion 2 and associated tests for diabetes and heart disease screening in community pharmacies in Canada. This agreement includes valuable HbA1c testing, a critical marker for the screening and management of diabetes.

Near Term Goals

Near term goals for Avricore include expansion into more pharmacies across Canada, followed soon after by entering the U.S. and UK markets. The company has made significant strides in testing and developing its technology and is moving into the commercialization stage.

Strategic partnerships like those with Abbott and select Shoppers Drug Mart pharmacies advance Avricore closer to becoming an incredibly dominant player in the community diagnostics space. The company aims to make actionable health information more accessible for everyone by creating the world’s largest rapid testing network in pharmacies.

Market Outlook

In 2020, the global point-of-care testing (POCT) market was valued at $34.49 billion and expected to expand at a compound annual growth rate (CAGR) of 9.4 percent to reach a projected $81.37 billion by 2028. This upsurge is expected to be driven largely by increased demand for screening and management tools for chronic diseases, as well as rapidly assessing infectious diseases such as COVID-19.

The accessibility of POCT has been an increasing priority of the world’s leading health organizations and experts. Pharmacies are ideal ‘hubs’ within the community to offer patients better access to the numbers they need to know for preventing or treating conditions such as diabetes and heart disease or the timely diagnosis of infection.

Management Team

Avricore’s leadership team brings a diverse portfolio of expertise across the health care and biotech industries, as well as technology, finance and communications. Together, they share a common vision of moving pharmacy forward and have positioned the company for significant future growth and expansion.

Hector Bremner is the CEO of Avricore. He has over 15 years of senior and executive experience across various industries, including international trade, natural gas, marketing and communications. He owned and operated TOUCH Marketing, a boutique marketing and communications firm based in Vancouver, from 2007 to 2013. Mr. Bremner has also served as the executive assistant to the Deputy Premier and Minister of Natural Gas Development, Responsible for Housing, as well as the Minister of International Trade and Minister of Small Business. In 2015, he joined Vancouver’s Pace Group Communications as VP of Public Affairs.

David Hall is the Chairman and a Director of Avricore. His leadership spans five different companies. He is currently the Chairman of RepliCel Life Sciences and a member of the boards of TrichoScience Innovations, AdvantageBC and Providence Health Care Research Institute. Mr. Hall also served as Chairman of Perceptronix Medical Inc.; Chief Financial Officer, Secretary & Treasurer of Angiotech Pharmaceuticals Inc.; President & Director at Newcastle Resources Ltd.; and Chairman for LifeSciences British Columbia.

Kiki Smith is Avricore’s CFO. She has over 20 years of experience assisting private and public companies in the roles of accountant, corporate controller and CFO in mining, oil & gas, real estate, high technology, food production and investment fund management. She currently provides consulting services in M&A, financial reporting and regulatory compliance to several public and private companies across several investment sectors. Ms. Smith is a member of the Chartered Professional Accountants of British Columbia and has a bachelor’s degree in economics from the University of British Columbia.

Rodger Seccombe is the Head of Avricore’s HealthTab division and the co-founder and former CEO of HealthTab Inc. Mr. Seccombe has over 20 years of experience launching and running companies in software, health care technology and clean energy. He is a recognized industry expert in direct-to-consumer and point-of-care testing technology. In 2006, he joined the start-up team at Canadian Bioenergy Corporation and helped pioneer the development of the renewable fuel industry in Canada. Before HealthTab, he designed and developed cloud-based informatics systems currently in use by some of the world’s leading medical laboratories and instrument manufacturers.

Avricore Health Inc. (OTCQB: AVCRF), closed Wednesday's trading session at $0.132, up 7.3258%, on 3,050 volume with 2 trades. The average volume for the last 3 months is 3,050 and the stock's 52-week low/high is $0.013269999/$0.485619992.

Recent News

• Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) - InvestorNewsBreaks - Avricore Health Inc.'s (TSX.V: AVCR) (OTCQB: AVCRF) HealthTab(TM) Demonstrates New, Better Way of Doing Pharmacy Practice
• Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Leveraging Data to Offer Patients, Drug Manufacturers, Researchers, Better Outcomes
• InvestorNewsBreaks - Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Supporting Pharmacists, Enabling Patients to Live Life Well

Mobius Interactive Ltd.

The QualityStocks Daily Newsletter would like to spotlight Mobius Interactive Ltd..

Mobius Interactive, an online esports and gaming operator, is seeing great success since its launch during the lockdown in 2020. The company differentiates itself from its competitors by its use of top affiliates, a focus on esports, customer relationship management, loyalty programs, and superior gamification. On the esports front, Mobius Interactive, through its flagship brand, Mobius.bet, is going to market in Brazil, the largest esports and gaming market in Latin America. “While this industry is experiencing unprecedented growth, Mobius.bet is perfectly positioned to take advantage of this lucrative emerging market,” reads a recent article. To showcase the brand, Mobius.bet sponsored Italy Serie A football games in Brazil in August, running on Band, ESPN and Fox, with each match featuring one of Italy’s Big 6 teams. “Serie A TIM is a professional league competition for football clubs at the top of the Italian football league.” Mobius Interactive CEO and Co-Founder Lynne Pearce described this unique opportunity: “As we go to market in Brazil, Mobius.bet will be showcased, featuring many of the best football players in the world. With our top sponsorship of the World Cup Qualifiers, coupled with our matches with Serie A, we couldn’t have asked for a better situation for our Brazilian launch.” To view the full article, visit https://ibn.fm/zwPUL

Mobius Interactive Ltd. is an online gaming operator launching in September 2020 with a variety of unique offerings catering to diverse demographic groups. In partnership with Ultra Play, a leading eSports and iGaming platform, Mobius Interactive is seeking to attract a network of high-net-worth gamers from around the world through the use of loyalty and gamification programs designed to enhance customer engagement by leveraging state-of-the-art customer relationship management systems and joint-ventures with over 600 VIP and Master gaming affiliates.

Array of Brands

Mobius Interactive is seeking to target a variety of customer segments and geographies through its diverse brand offerings, including:

• Aragon Casino: Austria, Finland, the Balkans, Canada, Africa and New Zealand
  Catering to consumers aged 21 to 45, Aragon Casino brands itself along the lines of medieval fantasy, mimicking elements from the likes of The Walking Dead and Game of Thrones.
• Club Double: Austria, India, Brazil, Finland, Canada, Africa and New Zealand
  Targeting the 30 to 65 age demographic, Club Double is designed to exude a classic yet magical old Hollywood and vintage Miami & Las Vegas air.
• MobiusBet: Germany, Austria, Switzerland, Brazil, Latin America, New Zealand and India
  MobiusBet is designed to appeal to the 18- to 38-year-old eSports community, bringing together loyalty programs, targeted gamification and product merchandising in one seamless package.

Key Differentiating Indicators

Mobius Interactive has designed its platform with a number of key differentiation traits relative to its target market. These include:

• The use of affiliates: Mobius Interactive has partnered with over 600 VIP and Master gaming affiliates, who will introduce high-value players to the company’s award-winning iGaming platform. Mobius added over 150 proven affiliates in Europe, Brazil, Finland and New Zealand over a period of just 20 days.
• eSports Focus: Mobius.Bet, Mobius Interactive’s dedicated eSports hub, will cater to the quickly growing eSports segment, which is expected to rise to a value of $1.7 billion in 2021. With Mobius’ COO being one of the original founders of the eSports.com brand, the company aims to capitalize on this growing segment of the gaming industry.
• Customer Relationship Management (CRM): Mobius has partnered with Solitics, a new and real-time CRM system, enabling the company to personalize customers’ gaming experiences in an interactive and highly intelligent manner.
• Loyalty & Gamification: Mobius Interactive is set to introduce a unique loyalty and gamification program designed to increase customer engagement from signup. Loyalty and gamification programs have been proven to increase daily active wagering volumes by 30% while simultaneously increasing daily player activity by 60%. Furthermore, the introduction of these programs can help lower the company’s customer acquisition costs while adding a differentiating element to its platform.

Partnership with Puurl

Puurl provides a solution that embeds eGaming platforms into any existing online e-commerce store. First, shoppers can install the Puurl add-on to their browsers. Then, when visiting their preferred e-commerce stores, players will be prompted to bet, with the potential to win the products they’re browsing. The Puurl solution enables e-commerce operators and eGaming platforms to earn additional gambling revenues – even when their players are shopping. Through its partnership with Puurl, Mobius Interactive will look to add a unique revenue stream to complement its core business operations.

Management Team

Lynn Pearce, CEO, is an experienced, data-driven, commercially focused, strategic brand marketer with over 15 years of proven success in the global gaming industry, from land-based casinos in the UK to online gaming companies offering sports betting, poker and casino games. She was head-hunted to join a startup in Prague that launched 26 casinos, becoming profitable within the first three months of operation, before she relocated to Malta to join a leading B2B casino software development company as head of marketing, where she led global marketing, PR, product development, branding and go-to-market campaigns, retaining full control of a six-month budget of €1 million to increase brand awareness and customer engagement. She recently returned to the B2C side of gaming to launch three new brands in Germany, Brazil and India. She writes articles regularly for Infinity Gaming Magazine and has been a judge for the prestigious International Gaming Awards, a significant event for the gaming industry held each year prior to the largest gaming exhibition of the year, ICE London.

Robin Lawson, Vice President & COO, has been involved in iGaming for over 10 years, successfully founding two VIP casino departments across international locations in Latin America, as well as startup company Tabella in Europe. He most recently co-founded and acted as COO for eSports.com, which raised over $5.5 million as a startup ICO and was sold to German media giant ProSieben. Lawson is also a senior iGaming consultant for startup casino groups and an advisor to blockchain-based tech groups. His long-time experience and proven track record in startup organizations demonstrate his operational leadership skills.

Nicholas de Freitas, Vice President, Marketing, is one of the pioneers of digital stills photography for major retail companies in Africa and Australia. He left to start up UrbanActive, an outsourcing agency, working as marketing project manager and implementing major retail projects. He received his certification in digital marketing from the University of Stellenbosch. He has worked over the past few years as the marketing manager for various poker rooms and casinos, liaising and building relationships with software developers, successfully implementing a number of casino and poker products and holding regular weekly report sessions with the heads of all divisions of the company, spanning South Africa, Canada, Malta, Norway and Costa Rica.

Gary Eldridge, Chairman, is an experienced entrepreneur with a history of working in the venture capital and private equity industry. He is skilled in capital markets, M&A and funding startups and is a strong business development professional. For the past 30 years, he has created and managed numerous public and private companies in Canada, the U.S., Amsterdam, London, Zurich, Dusseldorf, Singapore and Panama. In addition to holding the role of chairman of the company, Eldridge is acting as a mentor to the team, assisting with the financials and structure of the company while allowing the team to be fully focused on Mobius’ growth and operations.

Recent News

• Mobius Interactive Ltd. - InvestorNewsBreaks – Mobius Interactive Ltd.’s Mobius.bet Poised in Lucrative Emerging Market
• InvestorNewsBreaks – Mobius Interactive Ltd. Is ‘Rising Star of the Year’ Finalist for Upcoming International Gaming Awards
• InvestorNewsBreaks – Mobius Interactive Ltd. Goes Live with First Esports Online Tournament into Latin American Market

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

As more countries adopt the use of renewable energies, people are encouraged to live more sustainably. Clothes made from hemp have become a popular alternative to the traditional poly-cotton blend, as the material is not only ecofriendly but also natural. With companies such as Flora Growth Corp. (NASDAQ: FLGC) set to take hemp textiles a notch higher, it may not be long before hemp clothing goes mainstream.

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

• Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
• Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
• Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

• Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
• Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
• Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.

Cultivation

Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Wednesday's trading session at $9.32, off by 0.107181%, on 1,395,014 volume with 9,757 trades. The average volume for the last 3 months is 1.317M and the stock's 52-week low/high is $2.8499999/$21.4500007.

Recent News

• Flora Growth Corp. (NASDAQ: FLGC) - 420 with CNW - Is Hemp Clothing as Sustainable as Claimed?
• Cannabis Weekly Round-Up: Tilray Asks for Investor Support
• 420 with CNW - Gallup Poll: Nearly 50% of Adult Americans Have Used Marijuana

Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX).

• Lexaria has progressed significantly in evidencing that its patented DehydraTECH(TM) drug delivery technology can sufficiently improve the usable fraction of known antiviral drugs that reach the bloodstream
• According to a Newsfile Corp. article, this technology can be applied to rendering treatments for HIV/AIDS and other infectious diseases more effective
• The company also released partial results from a human clinical study evaluating DehydraTECH-processed CBD for potential application against hypertension, which evidenced a rapid and sustained drop in blood pressure
• Growing hypertension and antiviral therapeutics market represent a potential win for Lexaria

In July, Lexaria Bioscience (NASDAQ: LEXX), a drug delivery technology developer, issued several key announcements that, in addition to highlighting the progress made in advancing its patented DehydraTECH(TM) drug delivery technology, form the basis of analysis in a recent Newsfile Corp. article (https://cnw.fm/gr5fu).

Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 19 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

• Speeds up delivery – the effects of the product are felt by the subject in just minutes.
• Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
• Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
• Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
• Reduces drug administration cost – lower doses mean lower overall drug costs.
• Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

• Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
• Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
• Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
• Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
• Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
• Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Wednesday's trading session at $6.21, off by 0.160772%, on 49,761 volume with 373 trades. The average volume for the last 3 months is 49,761 and the stock's 52-week low/high is $3.97510004/$12.50.

Recent News

• Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX) - Lexaria Bioscience Corp. (NASDAQ: LEXX) Targets Burgeoning Hypertension, Antiviral Therapeutics Markets with Drug Delivery Technology
• CannabisNewsBreaks - Lexaria Bioscience Corp.'s (NASDAQ: LEXX) Technology Is 'Outrageously Fast' in Oral to Bloodstream Delivery
• Podcast Notes Blood Pressure Drug Delivery Trial Successes of Innovative Lexaria Bioscience Corp.'s (NASDAQ: LEXX) Technology

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

• Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on psychedelic pharmaceutical therapies, has announced that Adelia Therapeutics Inc., its wholly controlled subsidiary, has reached key milestones for Year 1 Q3. The milestones were outlined in last year’s transaction agreement between Cybin, Cybin Corp., Cybin US Holdings Inc. and previous shareholders of Adelia. Based on the agreement, 9,392.6 Class B common shares in the capital of Cybin will be issued to Adelia shareholders; the issuance is designed to satisfy the approximately $251,581.81 owed to the shareholders upon Adelia meeting the outlined milestones. The announcement noted that the Class B shares are exchangeable for common shares in the capital of Cybin on a 10 Cybin shares for 1 Class B share ratio; the announcement also outlined additional guidelines and restrictions, including that no Class B Shares can be exchanged before Dec. 14, 2021. To view the full press release, visit https://ibn.fm/EEDbC
• A survey on mood disorders that was recently published by the National Alliance on Mental Illness has found that cost is the main obstacle hindering individuals from accessing mental health care. Cost was also found to be the main reason individuals who were able to access care had to discontinue their treatment. Many companies such as Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are working to develop treatments that will take mental health care to levels never seen before. Such novel remedies could come in handy in the wake of the COVID-19 induced spike in mental health disease rates.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Wednesday's trading session at $2.63, off by 6.0714%, on 1,238,731 volume with 4,631 trades. The average volume for the last 3 months is 1.229M and the stock's 52-week low/high is $0.493800014/$3.38000011.

Recent News

• Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) - More Americans Now Seeking Mental Health Treatment, Survey Finds
• InvestorNewsBreaks - Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports on Milestone Achievements Reached by Subsidiary
• Cybin Announces Additional Adelia Milestone Achievements

Ideanomics Inc. (NASDAQ: IDEX)

The QualityStocks Daily Newsletter would like to spotlight Ideanomics Inc. (NASDAQ: IDEX).

The board of directors of IDEX Biometrics ASA has resolved to issue 913,198 ordinary shares at NOK 2.10 per share to employees who participate in the company’s 2020 Employee Share Purchase Plan (2020 ESPP), which plan was approved by the annual general meeting on 15 May 2020. 53 employees participated in the 2020 ESPP in this cycle. The participating employees have elected to invest a part of the base salary in ordinary shares in the company. Purchase takes place every three months. The shares are restricted for three months.

Ideanomics Inc. (NASDAQ: IDEX) is a global company facilitating the adoption of commercial electric vehicles and supporting next-generation financial services and fintech products. Ideanomics is currently divided into two divisions – mobility and capital. These divisions provide shareholders with access to disruptive and high-growth opportunities.

The company expects 2021 to be another growth year after it raised approximately $400 million over the past six months. This funding has already been put to good use with acquisitions of Wireless Advanced Vehicle Electrification (WAVE) and Timios. With roughly $200 million still on the balance sheet, Ideanomics continues to look for new investments and acquisitions in revenue-based opportunities focused on EV and fintech businesses.

Founded in 2004, Ideanomics is headquartered in New York, New York, with additional offices in Hangzhou, Beijing and Qingdao, China. Its current operations span the United States, China, Ukraine and Malaysia.

Ideanomics Mobility

Ideanomics Mobility is focused on the EV market. The global commercial EV market was valued at $34.7 billion in 2018 and is expected to grow at a CAGR of 39.9% through 2022 to reach a total of $132.73 billion (https://ibn.fm/pPrf4). According to a survey by Grand View Research, the global EV charging infrastructure market is also expected to grow and reach $144.97 billion in 2028, expanding at a CAGR of 33.4% from 2021 to 2028.

This growth is expected to be driven by increased support of electric vehicles from the public, as well as the current U.S. administration, which has a goal of achieving a 100% clean-energy economy.

The Ideanomics Mobility unit consists of five companies:

• Mobile Energy Global (MEG) – Wholly owned China-based service provider of the Sales-to-Finance-to-Charging (S2F2C) business model to assist commercial fleet operators on EV enablement. Recent sales include 2,000 units of D1, BYD’s custom electric ride-hailing vehicle.
• Medici Motor Works – Wholly owned North America division. MMW will develop zero-emissions specialty vehicles, trucks, buses and vans for the North American market.
• Wireless Advanced Vehicle Electrification (WAVE) – Wholly owned Utah-based commercial EV charging technology company with a specialized offering of in-ground wireless charging for commercial vehicles. WAVE’s chargers power the Antelope Valley Transportation Authority, the largest municipal EV bus system in the country. Its revenue for 2020 exceeded $7 million, and it boasts a robust pipeline for 2021 and beyond.
• Treeletrik – Majority investment in Malaysian-based OEM will service a high-demand market – electric delivery mopeds. Treeletrik has obtained certifications in Thailand and Indonesia, with orders secured for 2021. Its North American marketing program is expected to commence in 2021. As a part of the ESG initiative, one tree will be planted for every unit sold.
• Solectrac – Minority investment in California-based electric tractor company. Solectrac manufactures 100% electric tractors to benefit farmers, crops and the planet at a time when the agriculture market remains virtually unaddressed by EV solutions.
• Silk EV – Minority investment in hyper car and performance car design company, which provides access to the high-end battery and charging technology development ecosystem.

Ideanomics is generating EV revenue from its Sales to Financing to Charging (S2F2C) business model, which features three operating areas:

1. Vehicle and Battery Sales: Medici, Treeletrik and Solectrac cover three key market segments
2. Financing, Leasing and Insurance: Offering financial services to fleet customers, commission delivery and origination fee-based revenue
3. Charging and Energy Services: Offering charging as a service, battery swap programs and WAVE wireless charging products

Ideanomics Capital

Ideanomics Capital is focused on providing disruptive fintech solutions across the entire board of financial services, ranging from financial markets to digital securities and assets to mortgages and more. More mainstream institutions and a growing number of companies have increased their digital securities services, along with institutional investments boosting bitcoin and the emergence of favorable regulatory developments, creating ample opportunities for widespread adoption of financial technologies.

Additionally, the U.S. real estate industry is ripe for technologization, as it currently is fragmented, antiquated, opaque and largely untouched by tech innovation. However, the expanding market, with U.S. home sales expected to grow 21.9% in 2021, and the increased digitization of all business spaces are expected to promote a digital-first experience as the new industry standard this year and beyond (https://ibn.fm/DwsUv).

The Ideanomics Capital unit consists of five companies:

• Timios – Wholly owned subsidiary bringing real estate into the 21st century by providing value-add, fee-based services addressing the title and closing process of home buying and mortgage transactions. Timios works to create transparency and efficiency within the market. Timios ended 2020 as a cash flow and EBITDA positive business.
• The Delaware Board of Trade (DBOT) – Wholly owned FINRA-regulated ATS and broker dealer based in Delaware.
• Liquefy – Minority investment bringing innovation to investment in real assets with blockchain technology by increasing efficiency in fractional ownership, lowering entry to investment barriers and unlocking liquidity in assets that were previously illiquid.
• Technology Metals Market (TM2) – Minority investment in UK company delivering a direct investment and trading market for technology metals with a newly accessible technology metals asset class for inventory diversification. The traded metals are 100% backed by physical metals.
• Intelligenta – Investment providing AI and machine learning solutions for financial institutions and regulators.

Management Team

Alf Poor is Ideanomics’ Chief Executive Officer. He is a client-focused and profit-driven executive who has a track record of success in rapidly growing technology companies and large, multi-national organizations. Mr. Poor’s expertise includes business planning, financing and creating and implementing corporate governance policies, as well as handling management across organizations. His specialization is working with cross-border and multi-national startups. Before taking the CEO role at Ideanomics, he was the CEO for Global Data Sentinel.

Conor McCarthy is the company’s Chief Financial Officer. He is a strategic and operationally oriented management-level professional. His extensive international experience is within the fintech, data science and advertising technology sectors. Mr. McCarthy has experience with public companies, PE, and VC-backed firms. His specializations are financial and management reporting, planning and analysis, financial modelling, performance metrics, KPIs, venture borrowing, Series A equity funding, ERP system implementation, international business operations, and acquisition due diligence and integration. Before joining Ideanomics, Mr. McCarthy most recently held a CFO position at OS33. Prior to that, he was CFO for Intent Media Inc.

Kate Lam is the company’s Managing Director of Financial Products. She is highly regarded for her fixed income capital marketing skills across Asia and the United States. Ms. Lam has over 25 years of experience in the financial markets industry, dealing with many asset classes and clients. Having spent a few years in the fintech startup industry, her skills bridge the gap between traditional financial assets and new technological innovations. She has held senior management positions at Bear Sterns, Deutsche Bank and Standard Chartered Bank.

Keith Byers is Ideanomics’ Senior Vice President of Operations. He has extensive experience managing strategic relationships with key clients and deepening the relationships through innovation and successful engagement strategies. Before Ideanomics, Mr. Byers was the Managing Partner and Head of Operations for Gain Theory. He has a Master of Arts – MA, Economics from Heriot-Watt University and a Master of Science – Economics from The University of Edinburgh.

Tony Sklar is the company’s Senior Vice President of Investor Relations. He is a communication strategist and has worked for multi-faceted companies with global operations. Mr. Sklar handles omni-channel distribution using intelligence platforms and data insights for strategic planning, international expansion and marketing channels. His specialties include project management with digital strategy and transformation, ICO, marketing, blockchain and strategic partnerships. In addition to his role with Ideanomics, he is also a board member for the Delaware Board of Trade and the host and senior technology reporter for Far From TV.

Ideanomics Inc. (IDEX), closed Wednesday's trading session at $2.41, off by 3.9841%, on 8,325,859 volume with 24,190 trades. The average volume for the last 3 months is 8.268M and the stock's 52-week low/high is $0.800000011/$5.5300002.

Recent News

• Ideanomics Inc. (NASDAQ: IDEX) - IDEX Biometrics: Employee Share Purchase Plan Share Issue - 1 September 2021
• InvestorNewsBreaks - Ideanomics Inc. (NASDAQ: IDEX) Announces Transformative Deal to Acquire VIA Motors
• Abu Dhabi Starts Levying Uniform Fees for EV Charging

Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2)

The QualityStocks Daily Newsletter would like to spotlight Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2).

Critical minerals are minerals that are important to the economy. A mineral’s criticality changes with time as society’s needs and supply shifts. Most critical minerals are metals that are essential to high-tech sectors. They include rare earth elements and metals such as platinum group elements, manganese, vanadium, molybdenum, cobalt, magnesium, gallium, tellurium and lithium. It may not be easy for the country to become self-sufficient in all critical minerals in the foreseeable future, and that means producers such as Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) may continue to play a role in meeting the demand for such metals in the U.S.

Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) (“Excellon” or the “Company”) is a silver and base metals producer with precious metal exploration and development projects in Mexico, Idaho and Germany. Since being founded in 1987, the Company has been advancing a precious metals growth pipeline focused on creating wealth for its stakeholders by realizing strategic opportunities in the silver and gold markets.

Excellon is an active and influential member of the Mining Association of Canada (“MAC”). The Company implements a practical, best-in-class management system that addresses the safety, health, security, environmental and community aspects of its operations, per the UN Sustainable Development Goals. On each project, the Company incorporates MAC’s Towards Sustainable Mining Initiatives and other world-class best practices with the objective of constantly improving its safety systems, training and hazard recognition.

Precious Metals Growth Pipeline

The Company is advancing a precious metals growth pipeline that includes: Platosa, Mexico’s highest-grade silver mine since production commenced in 2005; Kilgore, a high-quality gold development project in Idaho with strong economics and significant growth and discovery potential; and an option on Silver City, a high-grade epithermal silver district in Saxony, Germany, with 750 years of mining history and no modern exploration.

Maintaining and developing this pipeline presents the Company with enhanced opportunities in the expanding precious metals market, which was valued at $193.3 billion worldwide in 2020 (https://nnw.fm/6nv5f). This market is expected to increase at a compound annual growth rate (“CAGR”) of 9% from 2020 to 2027, resulting in an estimated $362.1 billion market size in 2027 (https://nnw.fm/6nv5f). Global market demand was calculated at 22,581.8 tons in 2020 and is expected to grow to 36,501.1 tons in 2027, achieving a CAGR of 3.5% (https://nnw.fm/6nv5f).

Excellon reported strong results in terms of both production and average pricing at the end of Q4 2020, including:

• Silver – 355,581 oz – $24.46
• Lead – 2,223,465 lbs. – $0.87
• Zinc – 2,452,728 lbs. – $1.21

Compared to Q4 2019, Excellon’s silver production increased by 37%, lead increased by 32% and zinc increased by 19% in Q4 2020 (https://nnw.fm/4C0P7).

Platosa Mine – Silver, Lead, Zinc – Production, Development & Exploration

The Platosa Mine is located 5 km north of Bermejillo, Durango, Mexico, on a 14,000-hectare property. The mine commenced production in 2005 as an underground operation and is 100% owned and operated by Excellon. The Company is mining massive sulfide ores rich in silver, lead and zinc from a series flat-lying massive sulfide bodies (mantos) in a carbonate replacement deposit system. Historically, the mining method was a modified room and pillar method, which transitioned to cut-and-fill in recent years and overhand-cut-and-bench in 2020. The ore produced from the mine is transported 200 km south for processing at the Company’s 100% owned Miguel Auza mill.

Kilgore Project – Gold – Exploration & Resource Growth

The Kilgore Project is located in Clark County, situated in eastern Idaho in the United States. The project area is 100% owned and operated by Excellon. While still in the exploration and development phase, the primary target on the 13,627-acre site is an epithermal gold system. The property itself has historical mining that dates back to the 1930s, with modern mineral exploration beginning in the 1980s. The Kilgore Project displays characteristics similar to Kinross Gold’s Round Mountain Mine, which has produced more than 15 million ounces of gold since operations began in 1977.

Evolución Project – Mineral Processing, Resource Growth & Exploration

The Evolución Project is located in Miguel Auza, Zacatecas, Mexico, and hosts a large gold, silver, lead and zinc epithermal within a 45,000-hectare property that is 100% owned by Excellon. The site includes a processing facility with a mill and flotation circuit which processes ore from Excellon’s Platosa mine. The facility has a capacity of 800 tons per day, with a 650 ton-per-day ball mill in operation and a second 150 ton-per-day ball mill on standby. Excellon is looking at opportunities for toll milling, expansion and economic study of the mineral resource and grassroots exploration. Importantly, the project covers an unexplored 35-kilometer strike of the Fresnillo silver trend, the richest silver belt in the world.

Silver City Project – Exploration

Excellon holds an option to acquire the 16,400-hectare Silver City Project in Saxony, Germany. Initial drilling results in 2020 confirmed the presence of a high-grade, district-scale epithermal silver system over more than 12 kilometers of strike. The Company is now focused on defining wider zones of mineralization (https://nnw.fm/jMah9). Silver City was mined from the 11th to late-19th century, until Germany moved off the silver standard in 1873. The deposits in the area were exceptionally high grade, with historical records indicating grades well in excess of 1,000 g/t silver.

Oakley Project – Exploration

The Oakley Project, located in Oakley, Idaho, is an exploration project with land holdings of approximately 7,000 acres. The project hosts gold-silver, epithermal hot spring-type mineralization at two targets: Blue Hill Creek and Cold Creek, and detachment-related gold-silver mineralization at Matrix Creek. The Company has granted Centerra (U.S.) Inc. an option to earn in to a 70% interest by, among other things, spending up to US$7 million in exploration expenditures on the project prior to May 2026.

Management Team

Brendan Cahill is the President & Chief Executive Officer of Excellon Resources Inc. He was previously Vice President Corporate Development of Pelangio Exploration Inc., a junior gold exploration company active in Ghana, West Africa. Mr. Cahill is a board member of the Mining Association of Canada, Group Eleven Resources Ltd., and Kore Mining Inc. He holds a law degree from the University of Western Ontario and an undergraduate degree from the University of Toronto.

Alfred Colas is the Company’s Chief Financial Officer. Most recently, he held the title of CFO of Arch Corp., a Toronto-based private-equity investment firm. Mr. Colas has over 18 years of experience in the mining industry. He is a sitting board member for a housing corporation affiliated with the University of Toronto and is a Chartered Professional Accountant. Mr. Colas completed a Bachelor of Commerce at the University of Toronto.

Paul Keller is Excellon’s Chief Operating Officer. He has over 30 years of industry experience in mining and mine development operations. He previously served as the Senior VP of Major Projects and COO of Trevali Mining. He has experience in building mines from greenfield through permitting, design and operation. Mr. Keller holds a Bachelor of Engineering – Mining from Laurentian University.

Ben Pullinger is the Senior Vice President Geology & Corporate Development for Excellon. Ben brings over 15 years of experience in advancing projects from early stage exploration through to production. Most recently, he was Vice President Exploration at Roxgold Inc., where he made a significant contribution toward growing the 55 Zone at Yaramoko Project into a producing mine. Mr. Pullinger serves on the board of Orford Mining. He is a Professional Geologist (Ontario) and holds an Honors Degree in Geology from the University of Johannesburg.

Excellon Resources Inc. (EXN), closed Wednesday's trading session at $1.86, off by 2.6178%, on 8,230 volume with 51 trades. The average volume for the last 3 months is 8,230 and the stock's 52-week low/high is $1.71000003/$3.90000009.

Recent News

• Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) - Report Finds Increase in US Critical Mineral Imports
• InvestorNewsBreaks – Emaginos Inc.’s Model Designed to Help Schools, Districts Save Money, Deliver High-Quality Education
• MiningNewsBreaks - Excellon Resources Inc.'s (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) Platosa Continues Production at Historically High Rates

The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER)

The QualityStocks Daily Newsletter would like to spotlight The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER).

The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER), the country’s largest independent alkaline water company and The Clean Beverage Company(TM), today announced that its one-liter and 700ml bottles of Alkaline88(R) will be available in over 100 retail locations in nine major U.S. airports. “With the rebounding of the airline industry, this was an ideal time for Alkaline88 to enter into this channel. The sales team and our new director of hospitality and foodservice, Gary Bliss, have done an amazing job securing this deal. Now, hundreds of millions of passengers will have access to Deliciously Smooth(TM) Alkaline88 as they travel through major airports to destinations around the world. Featured in over 100 retail locations, our brand will be accessible to every passenger that enters these terminals,” said Ricky Wright, president and CEO of The Alkaline Water Company. “These airports represent nine of the top 30 airports in North America. They include the big three in New York City area—JFK, LaGuardia and Newark— Chicago O’Hare, Reagan National, Orlando International, George Bush Intercontinental/Houston, Minneapolis-St. Paul International, and Philadelphia International. In 2019, over 400 million passengers flew out of these airports.” To view the full press release, visit https://ibn.fm/r6GPD

Founded in 2012, The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER) is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88®, is a leading premier alkaline water brand available in bulk and single-serve sizes, along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88® delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts the company’s trademarked label ‘Clean Beverage’. Quickly being recognized as a growing lifestyle brand, Alkaline88® launched A88 Infused™ in 2019 to meet consumer demand for flavor-infused products. A88 Infused™ flavored water is available in six unique all-natural flavors, with new flavors coming soon. Additionally, in 2020, the company launched the A88CBD™ brand, featuring a broad line of topical and ingestible products. These products are made with lab-tested full and broad-spectrum hemp and include salves, balms, lotions, essential oils, bath-salts, CBD infused drinks, tinctures, capsules, gummies and powder packs.

Innovation and Expansion

Founded in 2012, The Alkaline Water Company began with a mission to create the best-tasting water in the world. At the time, there were two emerging trends in health-conscious consumers: a growing interest in the alkaline diet and perceived health benefits of pink Himalayan rock salt. By combining these two concepts in an alkaline water and trademarking the name Alkaline88, The Alkaline Water Company began offering what it calls the smoothest tasting Clean Beverage™ in the U.S. enhanced-water category.

Now a top bulk alkaline-water brand (the company reported record sales in March and April 2020, surpassing March and April 2019 numbers by 114% and 171%, respectively), The Alkaline Water Company is committed to growing its national footprint through innovation and expansion. That mindset was evident as the company introduced eco-friendly aluminum bottles and branched out into flavor-infused waters; the company currently offers six different flavors: peach/mango, lemon/lime, raspberry, watermelon, blood orange and lemon.

The company’s commitment to innovation may be most evident in its newest product line: A88CBD. This line of CBD-infused products includes tinctures, capsules, gummies, salves, balms, hand and foot lotions, essential oils, bath bombs and bath salts, as well as CBD-infused drinks, water and beverage shots. These quality, CBD-infused offerings are all made with lab-tested, full-spectrum hemp and are conveniently packaged and perfect for on-the-go or at home use.

In addition, The Alkaline Water Company has implemented an aggressive growth strategy, with numerous organic initiatives focused on national multichannel, mass-market expansion through a direct-to-warehouse model and co-packing facilities that are strategically located within 600 miles of 95% of the U.S. population. In addition to this strong brick-and-mortar approach, the company recently launched a B2C e-commerce platform (www.A88CBD.com) and aggressive digital-marketing campaigns.

Clear Advantages in a Growing Market

With consistent growth year over year, the company reported $32.2 million in revenue in fiscal 2019 and has emerged as a growth leader in the functional (value-added) waters space, which is the fastest-growing segment of the bottled water industry.

The Alkaline Water Company’s efforts are focused on its clear competitive advantages, including its strong marketing (the inclusion of alkaline in product names); existing grocery channels, which feature excellent relationships and a nationwide broker network; distinctive branding; proprietary technology, which produces great-tasting, high-quality water, infused drinks and other products; and price, with a broad range of products in all formats, from bulk bottles to single serve.

As the company focuses on strategic growth, it is eyeing the impressive potential of a market that is on a strong upswing. Annual bottled water sales have now surpassed soda consumption, with soda sales in the United States having declined by $1.2 billion over the past five years. Some research indicates that the global bottled water market will reach an estimated $280 billion this year, while the CBD market is forecast to top $20 billion by 2024.

With its products available in all major trade channels, including grocery stores, drug stores, c-stores and big-box retailers, The Alkaline Water Company is also looking to expand into new spaces, such as health and beauty, hospitality and specialty retailer locations.

Seasoned Management Team

The Alkaline Water Company is led by an experienced team focused on the company’s core strategy of building a national retail footprint and extending its lifestyle brands into other consumer packaged goods categories.

Richard A. Wright, President, CEO and Co-Founder of The Alkaline Water Company Inc., oversees all aspects of the business, successfully guiding the company through strategic opportunities and delivering greater than 50% growth since the company’s inception. A passionate and versatile leader with a strong track record of innovation, collaboration and achieving goal-driven results, Wright is a serial entrepreneur with more than 41 years of experience. Early in his career, he spent years at one of the ‘Big Four’ accounting firms, working his way up to Regional Director of Tax and Financial Planning. As a CPA, entrepreneur and former CFO, Wright brings extensive knowledge of finance, operations, sales and marketing to the team, and he has participated in hundreds of M&A transactions throughout his career.

David Guarino, CFO, Secretary, Treasurer and Director, earned a Bachelor of Science in accounting and a Master of Accountancy from the University of Denver. From 2008 to 2013, Guarino was President and a Director of Kahala Corp., a worldwide franchisor of multiple quick-service restaurant brands with locations in 49 states and more than 25 countries. From 2014 to 2015, Guarino was President of HTI International Holdings Inc., a technology company focused on forward osmosis water filtration technology.

Frank Chessman, National Sales Manager, is a graduate of the University of Southern California’s Marshall School of Business. He spent 25 years with Ralph’s Grocery, Kroger’s largest division, working at many levels before ultimately becoming Vice President of Advertising & Marketing. He then served 14 years as Executive Vice President at Simon Marketing. Chessman has more than a decade of experience in the beverage manufacturing industry.

Brian Sudano, Director, is managing partner of Beverage Marketing Corporation and BMC Strategic Associates. Sudano’s experience covers nearly the entire beverage industry, from energy drinks to wine, with special expertise in beverage alcohol by virtue of varied industry experience across a broad range of projects. Sudano manages several major clients, providing ongoing strategic and market advice and leading projects in strategic planning, market entry analysis and planning, sales/distribution, business modeling, brand repositioning and international opportunity assessment. He has spoken at many beverage industry events and is a contributing editor at Beverage World magazine.

Aaron Keay, Chairman, has been a successful investor, entrepreneur and financier to multiple small cap and startup companies over the last decade. During his time with these companies, he served in advisor, board-member and senior-management roles. His experience ranges across multiple sectors in mining, biotech, health and wellness, tech and cannabis, where he has invested and raised more than $500 million.

The Alkaline Water Company Inc. (NASDAQ: WTER), closed Wednesday's trading session at $1.79, off by 4.2781%, on 1,388,868 volume with 4,054 trades. The average volume for the last 3 months is 1.383M and the stock's 52-week low/high is $0.930000007/$2.3499999.

Recent News

• The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) - InvestorNewsBreaks - The Alkaline Water Company Inc.'s (NASDAQ: WTER) (CSE: WTER) Alkaline88(R) Coming Soon to 9 Major US Airports
• 420 with CNW - Why Similar Doses of Cannabis Edibles Could Have Vastly Different Effects
• The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER) Chair, the Shaq Invest $2M-Plus in Private Placement

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF)

The QualityStocks Daily Newsletter would like to spotlight Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF).

• Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, today announced that it will present at the H.C. Wainwright Annual Global Investment Conference. The event is slated to be held virtually on Sept. 13-15, 2021. Greg McKee, chairman and CEO of Tryp, will provide an overview of the company and its pipeline including Tryp's Psilocybin-for-Neuropsychiatric Disorders (“PFN”(TM)) program for chronic pain and eating disorder indications. Interested parties should visit https://ibn.fm/AkhYM to register and access the presentation. To view the full press release, visit https://ibn.fm/SqcMs
• If you’re interested in psychedelics and have watched the “Adventures in Psychedelics” documentary on Netflix, you may soon be getting a sequel. The documentary’s writer, Donick Cary, recently revealed that a series or film — or both — is on the horizon, hinting at the possibility of a podcast as well. This improved public perception of psychedelics is likely to give any medicinal formulations developed by companies such as Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) fertile ground on the market once patients and clinicians learn that approved psychedelic remedies now exist.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company focused on developing clinical-stage compounds for diseases with high unmet medical needs through accelerated regulatory pathways.

The company was founded in 2019 and is headquartered in San Diego, California.

Innovative Drug Pipeline

Tryp’s current focus is on advancing its two drug development platforms: its Psilocybin-for-Neuropsychiatric Disorders (PFN™) program targeting fibromyalgia, eating disorders and chronic pain conditions; and razoxane for soft tissue sarcomas. The company intends to explore opportunities to monetize these platforms after generating Phase 2b clinical data.

The company’s development plans cover three strategic initiatives:

• Develop: Tryp intends to utilize the FDA’s 505(b)(2) regulatory pathway with available third-party preclinical data to shorten the timelines and lower the cost of its development programs.
• Protect: Tryp plans to utilize regulatory exclusivity, patents, trade secrets and proprietary know-how to protect the commercial lifespan of its drug candidates.
• Monetize: Tryp intends to seek out licensing, acquisition and co-development opportunities for drug candidates following their Phase 2 stages of development.

PFN™ Program

Through its PFN™ program, the company is focused on developing psilocybin-based drug therapies for certain neuropsychiatric disorders that have distinct advantages over other drugs currently on the market or in development. These advantages include:

• Increased efficacy
• Natural blood-brain barrier penetration
• Enhanced safety and toxicity profiles
• Reduced risk of abuse
• Reduced risk of addiction

Tryp’s PFN™ program features its lead drug candidate, TRP-8802. The company’s initial indication for TRP-8802 is fibromyalgia.

Fibromyalgia is believed to be a neurosensory disorder characterized in part by abnormalities in pain processing by the central nervous system. The three drugs with FDA approval for the treatment of fibromyalgia are Pregabalin (Lyrica®), Duloxetine (Cymbalta®) and Milnacipran (Savella®), which are only effective for a portion of patients suffering from the condition.

Tryp plans to seek FDA approval to proceed directly to Phase 2 clinical trials evaluating TRP-8802 as a treatment for fibromyalgia based on existing preclinical and clinical data for the active pharmaceutical ingredients in TRP-8802.

Tryp’s pipeline of indications for TRP-8802 also includes eating disorders and certain forms of chronic pain. The company expects to initiate Phase 2a clinical trials in these areas in 2021.

Tryp recently partnered with Albany Molecular Research Inc. (“AMRI”) for the manufacture of the company’s synthetic psilocybin using proprietary methods. AMRI has initiated the process of manufacturing a 200g non-GMP demonstration batch of psilocybin and will produce a batch of GMP psilocybin in mid-2021. As the holder of the Drug Master File, Tryp expects to be the only U.S.-based manufacturer of synthetic psilocybin in the industry.

Razoxane

Tryp’s second drug candidate, TRP-1001 (razoxane), is being developed as a treatment for soft tissue sarcomas and has been evaluated in multiple Phase 2 clinical trials conducted by clinicians unaffiliated with Tryp. The company believes that existing clinical data regarding razoxane will likely allow TRP-1001 to be studied in a Phase 2 trial without the need for extensive preclinical or Phase 1 trials.

Sarcomas are rare tumors that are derived from connective tissues in the body and comprise 7% of all cancers in children. In 2018, an estimated 13,000 new cases of soft tissue sarcoma were diagnosed, with the tumors resulting in over 5,000 deaths during that year in the United States alone (https://ibn.fm/nWOGq).

Market Outlook

With its drug development programs targeting multiple indications, Tryp is well positioned to capitalize on growth opportunities spanning a range of therapeutic markets. The global oncology drugs market, in particular, represents a sizable opportunity.

In 2018, oncology indications accounted for 25% of all drug sales, representing approximately $151 billion in market revenues. By 2024, spending on oncology-targeted therapeutics is expected to top $200 billion and account for roughly 30% of total drug sales, according to a study by Cowen Equity Research (https://ibn.fm/9iZhM).

Valued at $764 million in 2020, the global fibromyalgia treatment market presents unique opportunities for development due to the limited number of approved therapies. With treatment trending upward, the market is expected to grow at a CAGR of 9.2% and reach $1.4 billion in value by 2027 (https://ibn.fm/G66e7).

Management Team

Greg McKee is the Chairman and CEO of Tryp Therapeutics. He has more than 20 years of life sciences management and venture investment experience that he brings to the company. Before taking his role at Tryp, he was the founder of Torrent Ventures, an early-stage digital health and medical technology venture fund. Mr. McKee also served as the CEO of CONNECT, the largest Southern California start-up accelerator. Before this, he was the chairman, president and CEO of then publicly traded Nventa Biopharmaceuticals, which successfully merged with Akela Pharma. Mr. McKee earned a B.A. in Economics from the University of Washington, an M.A. in International Studies from The Joseph H. Lauder Institute, and an MBA from the Wharton School at the University of Pennsylvania. He has been a member of the Young President’s Organization (YPO) since 2006.

James Gilligan, Ph.D., is the company’s President and Chief Science Officer. He has over 35 years of experience in the life sciences industry, including research and development, clinical development, international regulatory affairs and manufacturing. Before joining Tryp, Dr. Gilligan was the Co-Founder and Managing Partner of The Bracken Group, a life sciences consulting firm. He was also the Co-Founder of Unigene Laboratories, which develops technology for the recombinant manufacture of peptide hormones. Dr. Gilligan received his Ph.D. in Pharmacology from the University of Connecticut and a MSIB from Seton Hall University. He continued his post-graduate education at the Roche Institute of Molecular Biology.

Tom D’Orazio is the Chief Operating Officer of Tryp Therapeutics. He has extensive experience in leading the development and commercialization of vaccines, drugs, radiopharmaceuticals and biologics. His prior leadership experience has been in commercial planning, marketing, partnership and business development roles. He was formerly the CEO of ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), where he led the transition from a private company to a public one. He co-founded and served as CEO of Superna Life Sciences, a specialty-pharma company focusing on niche drugs for cancer patients in Canada. Mr. D’Orazio has an MBA from Vanderbilt University with a primary focus in both finance and marketing and a B.Sc. in chemistry from Loyola University of Chicago.

Luke Hayes is the company’s Chief Financial Officer. He has played an active role in the life science industry for over 20 years with technology transfer, venture capital and finance experience. His career started with business development for Dow Chemical (NYSE: DOW), with responsibility for pharmaceutical customers such as Eli Lilly and AbbVie. Mr. Hayes has spent more than a decade doing venture capital investing while supporting companies as a director and advisor. He earned a B.S. in Chemical Engineering from Brigham Young University and an MBA from the UCLA Anderson School of Management.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), closed Wednesday's trading session at $0.3622, off by 0.767123%, on 78,610 volume with 46 trades. The average volume for the last 3 months is 78,610 and the stock's 52-week low/high is $0.322299987/$1.03999996.

Recent News

• Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) - Filmmaker Behind Netflix's Psychedelics Documentary Is Working on Sequel
• InvestorNewsBreaks - Tryp Therapeutics Inc. (OTCQB: TRYPF) (CSE: TRYP) to Present at H.C. Wainwright Global Investment Conference
• InvestorNewsBreaks - Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Featured in Equity Research Report

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF)

The QualityStocks Daily Newsletter would like to spotlight PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF).

PlantX Life (CSE: VEGA) (OTCQB: PLTXF) (Frankfurt: WNT1) today announced the launch of its redesigned Canadian website www.PlantX.ca, powered by Shopify. The new website features a refreshed and modern design, simplified navigation and upgraded search tools and functionality to enhance overall user experience and brand impact. “The decision to transition to Shopify as the main e-commerce platform to host the PlantX online presence is a strategic move that complements the company's mission and expansion plans,” said PlantX Founder Sean Dollinger. “By leveraging the Shopify embedded features, PlantX will be able to replicate its current Canadian model and launch additional websites in other countries.” To view the full press release, visit https://ibn.fm/0p6e3

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) aims to redefine the plant-based community through e-commerce, with a core objective of becoming the most trusted and convenient destination for people living plant-based lives. PlantX is a multifaceted marketplace providing consumers all things plant-based ranging from an efficient e-commerce experience, connecting consumers with interactive PlantX brick-and-mortar stores, and a PlantX home delivery system for products, meals, recipes and more.

PlantX is a high-growth technology company focusing on consumer-packaged goods (“CPG”) for the plant-based opportunity. The PlantX platform aims to serve as the digital face of this community with its one-stop-shop for everything plant-based, including:

• An easy-to-use e-commerce shopping experience featuring the following:
• Plant-based grocery items (from all your pantry needs to vitamins, cosmetics and even pet food)
• Meal delivery with recipes created by well-known plant-based chefs throughout the world
• Plant shop – delivering a wide variety of affordable indoor houseplants to homes across Canada and the U.S.
• Easy to follow plant-based recipes every week
• Partnerships with restaurants, nutritionists, chefs and brands
• A community of like-minded individuals
• State-of-the-art flagship PlantX locations

Since first launching in February 2020, PlantX Life has offered various services available through its comprehensive platform. This online marketplace features over 10,000 items across diverse product categories such as pantry items, beverages, personal care, pet food and indoor plants. In addition, PlantX has collaborated with renowned chefs and nutritionists to create 20 unique and pre-made meals delivered to the comfort of your own home.

Headquartered in Vancouver, Canada, PlantX’s mission is to spearhead the plant-based movement, celebrate and promote health and wellbeing, raise plant-based awareness in a hyper-palatable world, connect with global consumers and forge a welcoming plant-based community.

The company currently reports 4 million stock options and 24 million warrants outstanding, with a total of 88,832,159 shares issued and outstanding and a total market cap of $89.9 million on January 18, 2021. PlantX has continued to catalyze its capital markets dynamics by applying to list its common shares on the Nasdaq Capital Market (“NASDAQ”). The company’s common shares are eligible for electronic clearing and settlement through The Depository Trust Company (“DTC”) in the United States.

Market Outlook

With its comprehensive e-commerce platform, PlantX is strongly positioned for a prominent role in the fast-growing plant-based food market, e-commerce and the online food delivery sectors. The global plant-based food market is expected to reach $74.2 billion by 2027, expanding at a CAGR of 11.9%. Similarly, the online food delivery market has steadily grown, especially during the current pandemic. This trend seems here to stay. In the United States alone, the sector is expected to report $28.5 billion by 2024, with companies such as UberEats experiencing 152% increases in food deliveries in the summer of 2020.

Complementary to these trends, and as a result of the COVID-19 pandemic, online sales and digitization have also both grown exponentially in 2020. Grocery shopping has seen a remarkable transition to e-commerce, with online grocery sales growing by 53% in 2020. Amid the pandemic-imposed physical interactions and related consumer behavior change, large retailers have been compelled to meet this surge in e-commerce demand. For example, Whole Foods Markets has increased its online sales capacity by over 60% in 2020. The global meal kit delivery system is also becoming increasingly popular and is expected to achieve a market value of $19.92 billion by 2027, expanding at a CAGR of 12.8%.

PlantX aims to capitalize on this anticipated exponential market growth of the plant-based, e-commerce and home-delivery industries.

Digital Platform for the Plant-Based Community

The digital interface provided by PlantX spans a health and wellness initiative that offers thousands of plant-based products, meal delivery, indoor plants, recipes and a community space for those who are like-minded about plant-based products and healthy lifestyles. PlantX has been compared to Amazon, except with a focused tailored selection of plant-based offerings.

PlantX provides everything a consumer needs for plant-based living at the click of a button. With PlantX, customers can:

• Shop
• Find recipes
• Read blogs
• Join a community forum
• Listen to podcasts
• View cosmetics
• Research vitamins
• Purchase plant-based pet foods
• Read corporate updates
• Subscribe to an insightful newsletter

The company’s website was designed with a user-friendly interface that allows customers to visit the site and easily find what they need. Forums for communicating with a plant-based community make it easier to swap recipes or locate the best restaurants serving vegan and vegetarian-friendly cuisine.

PlantX Flagship Locations – British Columbia (Canada), San Diego (California), & the State of Israel

PlantX will link the e-commerce platform to flagship brick-and-mortar stores for a highly sensory customer experience. This is anticipated to drive corporate growth and global brand recognition.

These PlantX branded flagship locations will first launch in:

• Squamish, British Columbia, Canada
• San Diego, California, United States
• Tel Aviv, State of Israel

Customer engagement, education and creating a global plant-based community will be furthered through this initiative.

PlantX Restaurant Partnerships

With consumers becoming better informed and more health and environmentally conscious, a growing number of restaurants will start catering to the needs of customers who are vegan, vegetarian, have food-allergies (or specialized diets), or simply want to eat healthier.

PlantX proactively aims to support this change and help restaurants meet the needs of the plant-based community. Restaurants that want to increase revenue, drive traffic and make an impact can therefore partner with PlantX to better serve their customers by expanding and refining their menus.

Future Goals for PlantX Life

Having successfully completed all of the milestones that PlantX had set-out to achieve in the second half of 2020, PlantX strives to continue scaling through organic growth, strategic partnerships and accretive M&A opportunities. The upcoming plans from PlantX includes a global expansion strategy for distribution in North America, Europe and Israel.

Verticals launched in 2020 include:

• New meals and programs by renowned chefs
• Flagship PlantX locations
• PlantX branded goods
• United States meal delivery and LIV
• Online peer-to-peer fitness

Management Team

Sean Dollinger, the Founder of PlantX Life Inc., has had a very active professional career that started when he was only 17. While still in college, he started a delivery service that soon became one of Canada’s largest delivery firms (before companies like Postmates and Uber Eats ever existed). In 2014, Mr. Dollinger founded Namaste Technologies, the largest international e-commerce distributor of vaporizers and accessories. He brought Namaste public and turned it into a $1.2 billion business in two years. After finding a plant-based diet himself, and seeing the massive benefits that it provided for him, he decided he wanted to find a way to give back to the community and focus on something he loves. PlantX Life was born from this desire and became his passion project. He truly walks the talk.

Julia Frank is the CEO of PlantX Life. She has an MBA in digital entrepreneurship, and, in her past roles, she set up renowned strategies for large corporations like BMW and Daimler in Germany. Beyond her professional business prowess, Ms. Frank finds tremendous joy in preparing delicious and nutritious plant-based meals and is the face of the company. She practices a healthy and active lifestyle that includes experiencing as many cultures as possible to add more knowledge of the industry at large. This globally inclusive perspective gives her the unique advantage of being able to see plant-based living from all angles.

Lorne Rapkin, CPA, CA, LPA, is the President and CFO of PlantX Life and is also a partner at Rapkin Wein LLP. He has experience with clients in almost every industry, including finance, professional services, real estate, automotive, media and manufacturing. Mr. Rapkin works very closely with investment and public firms, seeking to comply with IFRS accounting standards. His roles often require him to work with management on go-public transactions, acquisitions and mergers. His keen attention to detail is an asset to any client he works with, and PlantX is no exception.

Alex Hoffman is the company’s CMO and has spent the last 10 years in the creative field cultivating her passion for design and appreciation for beauty. This is apparent in all of the creative decisions and outcomes seen at PlantX. Her role within the company is to oversee all of the brand marketing activities, establish and execute key processes for rapid growth, and work closely with management to refine the brand’s message for key segments and emerging opportunities. She has a sharp vision for exactly what’s needed to convey the company’s core messages and principles to both the public and investors, and she is a visionary with respect to creative marketing ideas and concepts.

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF), closed Wednesday's trading session at $0.305, off by 3.1746%, on 1,080,643 volume with 483 trades. The average volume for the last 3 months is 1.081M and the stock's 52-week low/high is $0.170000001/$1.85000002.

Recent News

• PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) - InvestorNewsBreaks - PlantX Life Inc. (CSE: VEGA) (OTCQB: PLTXF) (Frankfurt: WNT1) Announces Q1 2022 Results
• PlantX Announces Q1 2021 Financial Results
• InvestorNewsBreaks - PlantX Life Inc. (CSE: VEGA) (OTCQB: PLTXF) (Frankfurt: WNT1) Is Leveraging Trends in Alcoholic Beverage, E-Commerce Sectors